AMRN
Amarin Corporation plc
Healthcare — Drug Manufacturers - General
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Price History
Fundamentals
| Market Cap | $334.25M |
| P/E Ratio (TTM) | - |
| Forward P/E | 16.27 |
| EPS (TTM) | $-1.60 |
| Dividend Yield | - |
| Profit Margin | -15.51% |
| Revenue Growth | 7.40% |
| ROE | -7.28% |
| Debt/Equity | 1.71 |
| Recommendation | None |
| Analyst Target | $12.50 |
| Analysts | 2 |
| Next Earnings | Jul 29, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 66.9 |
| Beta | 0.83 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $20.90 |
| 52-Week Low | $12.96 |
| 50-Day Avg | $14.77 |
| 200-Day Avg | $15.42 |
| Avg Volume | 84.1K |
| Volume | 35.5K |
Performance Analysis
NEUTRALAMRN presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report